[ 125 I], [ 127 I]‐and [ 14 C]‐Labelling of the GLP‐1‐(7‐37) derivative NN2211 | Zendy

Kristensen Jesper B. | Zendy; Pedersen Mette L. | Zendy; Larsen Ulla D. | Zendy; Martiny Lars | Zendy; Hansen Louis B. | Zendy; Foged Christian | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

[ 125 I], [ 127 I]‐and [ 14 C]‐Labelling of the GLP‐1‐(7‐37) derivative NN2211

Author(s) -

Kristensen Jesper B.,

Pedersen Mette L.,

Larsen Ulla D.,

Martiny Lars,

Hansen Louis B.,

Foged Christian

Publication year - 2003

Publication title -

journal of labelled compounds and radiopharmaceuticals

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.432

H-Index - 47

eISSN - 1099-1344

pISSN - 0362-4803

DOI - 10.1002/jlcr.689

Subject(s) - chemistry , labelling , hydrogen peroxide , adme , derivative (finance) , lactoperoxidase , combinatorial chemistry , stereochemistry , biochemistry , pharmacology , enzyme , peroxidase , medicine , economics , financial economics , in vitro

Arg 34 Lys 26 ( N ε ‐(γ‐ L ‐glutamyl( N α ‐palmitoyl)))‐GLP‐1(7‐37) (NN2211) is currently in development as a diabetes type 2 drug. The fatty acid attached to the GLP‐1(7‐37) ensures a long and controlled duration of action. The synthesis of [ 125 I]NN2211, [ 127 I]NN2211 and [ 14 C]NN2211 used for preclinical ADME studies are described. NN2211 was iodinated using the lactoperoxidase/hydrogen peroxide method, and [ 14 C]NN2211 was synthesized in 4 steps by two routes both starting from an α‐protected [U‐ 14 C]glutamic acid. Copyright © 2003 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research